⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NXL News
Nexalin Technology, Inc. Common Stock
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
globenewswire.com
NXL
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
globenewswire.com
NXLIW
NXL
NeuExcell Therapeutics Announces Encouraging Data of NXL-004 in Recurrent Malignant Glioma at 2026 ASCO
globenewswire.com
NXL
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
globenewswire.com
NXLIW
NXL
Form 8-K
sec.gov
NXL
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
globenewswire.com
NXL
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
globenewswire.com
NXLIW
NXL
Form 8-K
sec.gov
NXL
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
globenewswire.com
NXL
RedChip's Biotech Investor Conference Replays Now Available
accessnewswire.com
SXTP
BIVI
BFRG
LTRN
NXL